QT Imaging Holdings, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025, reporting record full-year revenue of $18.9 million, exceeding guidance, and shipping 40 scanners. The company affirmed its 2026 revenue guidance of approximately $39 million, driven by distributor partnerships and the QTI Cloud Platform. Key achievements include FDA clearance for an updated scanner configuration, approval of a new Category III CPT code for its Breast Acoustic CT, and significant financial strengthening through a private placement.
QT Imaging Holdings, Inc. announced the first commercial sale of its QTI Breast Acoustic CT™ System to True Health Center for Functional Medicine, following a strategic distribution partnership. This innovative system aims to improve breast imaging by eliminating compression, radiation, and the need for contrast agents, focusing on patient comfort and safety. The technology, validated by the National Institutes of Health, provides high-quality 3D images and addresses limitations of traditional methods, especially for dense breast tissue.
QT Imaging Holdings (QTI) has released a new investor presentation detailing supplemental product and operational information, including its FDA-cleared QT Breast Scanner. The presentation aims to manage investor expectations by providing regulatory context, financial metrics, and extensive risk disclosures. Spark, TipRanks' AI Analyst, rates QTI as "Neutral" due to weak financial performance tempered by recent positive corporate updates.
